Due Diligence and Art

Due Diligence and Art

mRNA, Gene Therapies and Biomanufacturing Fraud

J&J settles by paying $50M to Emergent for their violation of FDA regulations in manufacturing J&J covid vaccine.

You read it correctly.

Sasha Latypova's avatar
Sasha Latypova
Jul 31, 2024
∙ Paid

On July 2, 2020, J&J (Janssen), then part of the Operation Warp Speed, entered into an agreement with Emergent BioSolutions for the manufacture of its viral vector-based COVID-19 vaccine.

Due Diligence and Art is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

However, Emergent was fou…

User's avatar

Continue reading this post for free, courtesy of Sasha Latypova.

Or purchase a paid subscription.
© 2026 Sasha Latypova · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture